DDD 3D Systems Corporation

3D Systems Announces Organization Changes and New Executive Leadership Appointments

3D Systems Announces Organization Changes and New Executive Leadership Appointments

  • Jeffrey Creech joins as Chief Financial Officer

  • Harriss T. Currie joins as President - Regenerative Medicine
  • New organization structure reflects technical progress and potential for significant value creation through new regenerative medicine technologies

ROCK HILL, S.C., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Today, (NYSE:DDD) announced two additions to its executive leadership team.

Effective today, December 13, Jeffrey Creech has joined the company as Executive Vice President and Chief Financial Officer. Mr. Creech will lead all facets of the company’s global finance organization.

Effective December 15, Harriss Currie will join the company in the newly created role of President - Regenerative Medicine. In this new role, Harriss will lead all elements of 3D Systems’ regenerative medicine efforts, ranging from the company’s partnership on human organs with United Therapeutics, to its recently formed Systemic Bio business, which is a wholly-owned subsidiary of 3D Systems that is focused on bioprinting solutions for the pharmaceutical industry. The creation of this new role reflects the increasing maturation of this exciting new technology, as it moves from early-stage conceptual development toward commercial application and the value the company believes it will someday bring to humanity.

Messrs. Creech and Currie will both report to 3D Systems’ President & CEO, Dr. Jeffrey Graves.

Mr. Creech joins 3D Systems with more than 25 years of experience in financial leadership and business transformation. He most recently served as Senior Director at the Finely Group, an executive advisory service company, and prior to that worked as Chief Operating Officer and Chief Financial Officer for Nutramax Laboratories, a privately held manufacturer of human and animal health dietary supplements.  Mr. Creech’s career also includes financial and operations roles with Springs Creative Products Group where he served as both President and Chief Operating Officer, and Jefferson Wells where he was the National Director, Business Transformation COE. He is a Certified Public Accountant and Certified Management Accountant and holds a bachelor’s degree in accounting from Pfeiffer University and a master’s degree in military studies/history from the American Military University.

Mr. Currie will be joining 3D Systems with 30 years of experience in executive leadership with a focus on building emerging businesses. He spent more than 20 years with Luminex Corporation, a DiaSorin Company, that is renowned for its biological testing technologies for life science applications. As Senior Vice President and Chief Financial Officer at Luminex, Harriss helped lead the company’s growth from a start-up to more than $500 million during his tenure. His career also includes senior finance leadership roles with Impulse Dynamics and SpectraCell Laboratories. Harriss earned his bachelor’s degree in accounting and economics from Southwestern University and his MBA, with a focus on Marketing and Finance, from the University of Texas at Austin.

“I’m pleased to welcome Jeffrey and Harriss to 3D Systems in these very important roles,” said Dr. Jeffrey Graves, president & CEO, 3D Systems. “Throughout their careers, both have brought their proven expertise and deep business acumen to bear to drive sustained customer and shareholder value. Jeffrey’s background and experience building and leading successful finance teams will be invaluable to our organization – helping us drive cost efficiencies to position us for long-term growth. Harriss’s experience in the biotech industry, combined with his financial and operational expertise, make him an excellent leader for our emerging regenerative medicine business, which holds such potential to benefit our shareholders and all stakeholders in our business. I am confident that both gentlemen will be integral in our journey as the leading additive manufacturing solutions provider.”

Dr. Graves continued, “I also wish to extend my heartfelt thanks to Andy Johnson who served as Interim CFO while we executed this search. Andy is a key member of our leadership team as Chief Corporate Development Officer and Chief Legal Officer. I am grateful that he seamlessly added the role of CFO to his plate. His leadership has been instrumental in this transition period.”

Forward-Looking Statements

Certain statements made in this release that are not statements of historical or current facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. In many cases, forward-looking statements can be identified by terms such as “believes,” “belief,” “expects,” “may,” “will,” “estimates,” “intends,” “anticipates” or “plans” or the negative of these terms or other comparable terminology. Forward-looking statements are based upon management’s beliefs, assumptions, and current expectations and may include comments as to the company’s beliefs and expectations as to future events and trends affecting its business and are necessarily subject to uncertainties, many of which are outside the control of the company. The factors described under the headings “Forward-Looking Statements” and “Risk Factors” in the company’s periodic filings with the Securities and Exchange Commission, as well as other factors, could cause actual results to differ materially from those reflected or predicted in forward-looking statements. Although management believes that the expectations reflected in the forward-looking statements are reasonable, forward-looking statements are not, and should not be relied upon as a guarantee of future performance or results, nor will they necessarily prove to be accurate indications of the times at which such performance or results will be achieved. The forward-looking statements included are made only as of the date of the statement. 3D Systems undertakes no obligation to update or review any forward-looking statements made by management or on its behalf, whether as a result of future developments, subsequent events or circumstances or otherwise, except as required by law.

About 3D Systems

More than 35 years ago, 3D Systems brought the innovation of 3D printing to the manufacturing industry. Today, as the leading additive manufacturing solutions partner, we bring innovation, performance, and reliability to every interaction - empowering our customers to create products and business models never before possible. Thanks to our unique offering of hardware, software, materials, and services, each application-specific solution is powered by the expertise of our application engineers who collaborate with customers to transform how they deliver their products and services. 3D Systems’ solutions address a variety of advanced applications in healthcare and industrial markets such as medical and dental, aerospace & defense, automotive, and durable goods. More information on the company is available at .

Investor Contact:
Media Contact:
  

Photos accompanying this announcement are available at:



EN
13/12/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on 3D Systems Corporation

 PRESS RELEASE

3D Systems Announces FDA Clearance for World’s First 3D-Printed PEEK C...

3D Systems Announces FDA Clearance for World’s First 3D-Printed PEEK Cranial Implants FDA clearance enables wide-spread adoption of 3D Systems self-contained, cleanroom environment-based printing system, the EXT 220 MED, with medical-grade PEEK materials to deliver patient-specific cranial reconstruction solutions3D-printed PEEK implants using the EXT 220 MED successfully demonstrated in nearly 40 cranioplasties across Europe in recent monthsMarket for cranial reconstruction anticipated to exceed $2 billion by 2030FDA clearance establishes strong foundation for expanded application of thes...

 PRESS RELEASE

3D Systems Receives NYSE Notice Regarding Late Form 10-K Filing

3D Systems Receives NYSE Notice Regarding Late Form 10-K Filing ROCK HILL, South Carolina, March 22, 2024 (GLOBE NEWSWIRE) -- (NYSE:DDD) (“the Company”) today announced that, on March 18, 2024, it received a notice (the “NYSE Notice”) from the New York Stock Exchange (the “NYSE”) that the Company is not in compliance with the NYSE’s continued listing requirements under the timely filing criteria established in Section 802.01E of the NYSE Listed Company Manual, because the Company has not timely filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the “Form 10...

 PRESS RELEASE

Wilting Expands Production Capacity with Three DMP Flex 350 Printers

Wilting Expands Production Capacity with Three DMP Flex 350 Printers Addition of single and dual laser printers enables use of broader materials portfolio to address new applications with Titanium, Stainless SteelDMP Flex 350’s best-in-class oxygen level (

 PRESS RELEASE

3D Systems Announces Additional Partial Repurchase of Convertible Seni...

3D Systems Announces Additional Partial Repurchase of Convertible Senior Notes Repurchasing approximately $110 million of 0% coupon, convertible senior notes at approximately 22% discount to par value Reduces remaining balance of outstanding notes to approximately $214 million, over 50% reduction from initial issued principal balance of $460 million, due 2026Reinforces balance sheet strength and maintains strong cash position to support operational needs ROCK HILL, S.C., March 05, 2024 (GLOBE NEWSWIRE) --   (NYSE:DDD) (“the Company”) today announced that it has entered into separate, pr...

 PRESS RELEASE

3D Systems Reports Fourth Quarter and Full Year 2023 Financial Results...

3D Systems Reports Fourth Quarter and Full Year 2023 Financial Results (Unaudited) ROCK HILL, S.C., Feb. 27, 2024 (GLOBE NEWSWIRE) --  (NYSE:DDD) announced today its financial results for the fourth quarter and full year ended December 31, 2023. Fourth Quarter Financial Results (Unaudited)(All numbers are unaudited and are presented in thousands, except per share amounts or otherwise noted) Q4 2023 revenue of $114,848 decreased 13.5% compared to Q4 2022 due to significant softness in dental orthodontics and depressed printer sales from delayed customer capex investmentsQ4 2023 gross pro...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch